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Abstract
PAX2, a member of the ‘‘paired-box’’ family of homeotic genes, is a nuclear transcription factor expressed in the early
stages of nephrogenesis by induced blastemal cells as they progress from mesenchymal condensates to the ‘‘S-shaped’’
stage and also by the ureteric bud. Spontaneous mutations in one copy of PAX2 in humans causes a syndrome of proteinuric
  . .renal failure and coloboma of the eye P. Sanyanusin et al., Nat. Genet. 9 1995 358–363 ; transgenic mice with disruption
  .of the PAX2 gene are anephric M. Torres et al., Development 121 1995 4057–4067. Although PAX2 is clearly critical
for normal kidney development, its direct effects on kidney cell phenotype are unknown. To address this issue, we
developed stable transfectants of the HEK293 human fetal kidney epithelial cell line expressing human PAX2 protein under
tetracycline-regulatable promoter. In these cells, PAX2 had no effect on the proliferative rate, but increased the expression
 .  .of the Wilms’ tumor gene 2-fold and E-cadherin 7-fold . PAX2 had a strong inhibitory effect on vimentin;
vimentinrGAPDH mRNA ratio was suppressed to 8% of control whereas cytokeratin-18rGAPDH mRNA ratio was
unchanged. During nephrogenesis, loss of vimentin and onset of low-level WT1 and E-cadherin expression occur in
mesenchymal condensates. Our observations suggest that these events may be, in part, regulated by PAX2. q 1998 Elsevier
Science B.V.
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1. Introduction
The metanephric kidney develops as a result of
reciprocal interactions between branches of the invad-
ing ureteric bud and adjacent cells of the undifferenti-
ated metanephric blastema. In response to signals
from the ureteric bud, clusters of blastemal cells are
) Corresponding author. Fax: q1-514 934-4359.
induced to aggregate and undergo conversion from
their mesenchymal phenotype into an organized layer
of polarized epithelial cells with a central fluid-filled
lumen. In turn, signals from the induced mesenchyme
cause the ureteric bud to branch repeatedly, forming a
system of collecting ducts which fuse with each
emerging renal vesicle. Each early renal vesicle then
elongates to form the glomerulus, proximal tubule,
loop of Henle and distal convoluted tubule of the
final nephron.
The molecular mechanisms which orchestrate con-
version of mesenchyme to epithelium are not well
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understood. However, it is likely that the inductive
signals from ureteric bud elicit expression of a new
panel of transcription factor genes in blastemal cells.
Among these is PAX2, a member of the ‘‘paired-box’’
 . w xPAX family of homeotic genes 3 . Interest in the
PAX genes as key developmental regulators has been
intensified by the fact that PAX gene mutations
consistently produce developmental malformations
w x4 . Mutations of PAX3 and PAX6 have been associ-
ated with several different human malformations in-
 . w xcluding Waardenburg syndrome PAX3 5,6 and
 . w xaniridia PAX6 7 ; PAX2 mutations produce a syn-
drome of renal dysplasia with proteinuric renal fail-
 . w xure and colobomas of the eye PAX2 1,8 .
In the developing kidney, PAX2 is detected in the
condensing mesenchyme and early epithelial struc-
tures derived from these cells the ‘‘comma’’ and
. w x‘‘S-shaped’’ bodies 9,10 . As the tubule elongates
and begins to differentiate into more mature nephron
w xsegments, PAX2 is rapidly downregulated 10,11 .
PAX2 is also detected in the branching ureteric bud,
and Dressler has postulated that it is a key transcrip-
tion factor orchestrating the pattern of gene expres-
sion during reciprocal interactions between ureteric
w xbud and blastema 12 . In fetal kidney organ culture,
antisense PAX2 oligonucleotides disrupt normal
nephrogenesis from mesenchymal cell aggregation
w xonward 13 . Deregulated overexpression of PAX2 in
transgenic mice results in cystic renal malformation
with congenital nephrotic syndrome and death in the
w xfirst days of life 12 , and transgenic mice homozy-
gous for disrupted PAX2 genes lack kidneys, ureters
w xand genital tracts 2 .
Although PAX2 clearly plays an important role in
kidney development, its precise influence on cell
phenotype is a matter of speculation. To address this
issue, we stably transfected a human fetal kidney cell
 .line HEK293 with a tetracycline-regulated PAX2
expression vector and examined the effect on cell
phenotype. Although this adenovirus-immortalized
cell line did not provide a system in which we were
able to assess putative effects of PAX2 on cell prolif-
eration, we could demonstrate that PAX2 modified
vimentin, E-cadherin and Wilms’ tumor gene expres-
sion in a pattern reiterating some of the events which
occur during the mesenchyme-epithelium transition
of early nephrogenesis in vivo.
2. Materials and methods
2.1. Stable tetracycline-regulatable HEK293 PAX2r
tTA transfectants
In order to generate HEK293 cell lines expressing
variable amounts of PAX2 protein under tetracycline
regulation, we subcloned the full-length human
 .PAX2a cDNA the gift of Dr. M. Eccles, Otago, NZ
into the multicloning site of the p10-3 regulatable
expression plasmid, the gift of Gossens and Bujard
w x14 . Initially, the hPAX2a cDNA was digested with
Nco1, filled in with Klenow enzyme, dephosphory-
lated with CIAP and attached to Bgl-II adaptors
 .Boehringer Mannheim . The construct was further
digested with Xba1, and the resultant 1.3 kb Bgl-
IIrXba1 fragment containing the whole human
PAX2a coding sequence was inserted into a pCMV5
 .expression vector gift of J. Pelletier . Integrity of the
nucleotide sequence and expression of hPAX2a pro-
tein were confirmed by direct sequencing and West-
ern blotting with anti-mPAX2 antibody before and
after subcloning the hPAX2a cDNA into the
EcoR1rXba1 sites of p10-3.
For use with the tTA-responsive hPAX2a expres-
sion vector above, the human embryonic kidney cell
line, HEK293, was obtained from ATCC aCRL-
.1573 and grown in plastic culture dishes in Dul-
 . becco Modified Eagle’s Medium DMEM Gibco-
. BRL supplemented with 10% FBS In Vitrogen,
.  .NY and 1% PenrStrep Solution Gibco-BRL . Cells
were plated at 500 000 per 100 mm dish, grown to
about 50% confluency and co-transfected by the cal-
 .cium-phosphate precipitation method with: A vari-
ous amounts of the tetracycline-repressorrVP16 plas-
 .  .mid tTA of Gossens and Bujard; B 1 mg of
 .pSV2Neo ATCC a37149 . At 16–20 h, the cells
were washed and fresh DMEM medium added. At
48 h, cells were trypsinized, split into 150 mm Petri
dishes and grown in the presence of 500 mgrml
 .G-418 Gibco-BRL . After 2–4 weeks, individual
clones were selected, expanded and analyzed for tTA
expression by transient transfection in the presence or
 .absence of tetracycline 1 mgrml with 0.1 mgrdish
 .of a test-plasmid, p10-3 gift of Gossens and Bujard ,
containing a b-galactosidase reporter cDNA under
control of the tTA-responsive minimal CMV pro-
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 .moter. A clone, HEK293rtTA a3 , exhibiting tightly
regulated b-galactosidase activity in these transient
transfection assays was selected for the studies be-
low.
HEK293rtTA-3 cells were used for a second round
of stable transfection with 10 mgrdish of p10-
3rhPAX2a and 1 mgrdish of pCMVHygro gift of
.Dr. J. Pelletier ; the transfected cells were detached
and replated in medium containing 180 mgrml hy-
 .gromycin Sigma . After 2–4 weeks, individual clones
were selected for tetracycline-regulatable hPAX2a
protein expression.
2.2. Stable HEK293 murine PAX2 transfectants
 .HEK293 cells were also transfected with: A
10 mg of plasmid expression vectors containing
murine mPAX2a or mPAX2b isoforms under the
 .  .control of pCMV gift of Dr. G Dressler ; B 1 mg of
pSV2Neo. Individual clones were selected in the
presence of 500 mgrml G-418.
2.3. Western immunoblotting
Protein extracts were prepared from mPAX2a,
mPAX2b and hPAX2artTA stable transfectants by
boiling cell pellets in 2= SDS loading buffer
100 mM TRIS baser2% SDSr 20% glycerolr 2%
.mercaptoethanolr0.01 mgrml bromophenol blue .
Samples were resolved on SDSr10% polyacrylamide
gels, electroblotted onto ECL membranes
 .Amersham and probed with polyclonal rabbit anti-
 .  .mPAX2 antibody 1:3000 gift of Dr. G. Dressler
followed by peroxidase-linked anti-rabbit IgG and
 .ECL detection Amersham .
2.4. Northern analysis
Total RNA from PAX2-expressing cells was iso-
w xlated using the NP-40rurea method 15 . Total RNA
 .20 mg from each sample was resolved on 1%
agaroserformaldehyde gels and transferred to nylon
 .Hybond N membranes Amersham and cross-linked
with UV light. cDNA probes were radiolabeled using
 .the DECAprime II DNA labelling kit Ambion .
Northern blots were prehybridized and then probed at
428C overnight in 50% formamide, 2.5= Denhardt’s
 .solution, 25 mM KPO4 pH 7.4 , 0.1% SDS, 10%
 .wrv dextran sulfate, 5= SSPE, and 200 mgrml
 .herring sperm DNA Sigma . The blots were then
washed twice in 2= SSPE, 0.2% SDS at RT for
20 min, and twice in 0.1= SSPE, 0.2–0.4% SDS at
60–658C for 20 min and exposed for 1–4 days to
 .BioMax MR X-ray film Kodak at y808C. Band
intensity was estimated by densitometry using NIH
Image 1.49 software and normalized for RNA load-
ing by reprobing each blot with GAPDH cDNA.
The following cDNA probes were used for North-
ern analysis of RNA from the transfected HEK293
w xcells: 0.45 kb Pst1 fragment of human vimentin 16 ;
w x0.8 kb EcoR1 fragment of human cytokeratin 18 17 ;
w x2.4 kb EcoR1 fragment of murine E-cadherin 18 ;
w x1.8 kb EcoR1 fragment of human WT1 19 ; 0.75 kb
w xPst1–Xba1 fragment of human GAPDH 20 , human
w x w xPAX8 21 , SLC3A1 22 .
2.5. Semi-quantitati˝e re˝erse transcriptase-PCR
analyses
The reverse transcription reaction was performed
using 2.5 mg total RNA in the presence of 1=
 .First-strand buffer Gibco-BRL , 10 mM DTT
 .  .Gibco-BRL , 500 mM dNTP mix Pharmacia ,
 .  .1.6 mg Oligo dT 12-18 Pharmacia , and 2 units of
 .Superscript reverse transcriptase Gibco-BRL in a
total volume of 20 ml. The RT mix was incubated for
10 min at 258C followed by 50 min at 428C. Reverse
transcriptase was then inactivated by heating the reac-
tants to 708C for 15 min.
PCR amplification was performed in 50 ml of 1=
 .PCR buffer Gibco-BRL containing 200 mM dNTPs,
 .2.5 units of Taq polymerase Gibco-BRL , 2 ml of
each RT product and 200 pmol of each primer. The
following conditions were established for DNA am-
plification in the linear range:
For human E-cadherin: Primers: 5X-CCTTCCTCC-
CAATACATCTCCC and 3X-TCTCCGCCTCCTTCT-
TCATC 22 PCR cycles: 948C=30 s, 588C=30 s,
.728C=45 s .
For human actin: Primers: 5X-GATTCCTATGTG-
GGCGA and 3X-CTGGAAGAGTGCCTCAGGGC 20
 .PCR cycles: 948C=60 s, 608C=60 s, 728C=90 s .
PCR products were resolved on 1.5% agarose gels
and blotted onto Hybond N nylon membranes. South-
ern hybridization was carried out according to the
w xprotocol described by Maniatis 23 . Southern blots
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were probed with the cDNAs for human E-cadherin
w x24 or human b-actin and exposed to BioMax X-ray
film for 8–12 h prior to densitometry using NIH
Image 1.49 software as above.
For detection of human WNT4: Primers: 5X-
G G TA A A G A C G TG C TG G C G A G and 3X-
CTGCAGCGTTCAGCCAGGTC 30 PCR cycles:
 .948=60 s, 608=60 s, 728=60 s .
Alkaline phosphatase assay: Alkaline phosphatase
activity was measured colorimetrically as described
w xby Borgers et al. 25 .
3. Results
3.1. Characterization of HEK293 cells
After screening a panel of renal cell lines for
properties relevant to early development, the embry-
onic kidney cell line, HEK293, was selected because
 .of several advantageous characteristics Table 1 . Like
the induced blastema, HEK293 cells express Wilms’
 .tumor gene WT1 , Wnt4 and low levels of PAX2
mRNA but no detectable PAX2 protein by Western
.immunoblotting . Like cells of the early ‘‘S-shaped’’
body during nephrogenesis, they express mRNA for
the epithelial cell marker, cytokeratin, but lack mark-
ers of highly differentiated tubular segments such as
alkaline phosphatase activity or cystinuria gene
 .  .SLC3A1 mRNA proximal tubule markers and
PKD1 or vasopressin receptor collecting duct mark-
.ers . The cells are of human origin and are readily
transfectable. One disadvantage, however, is that these
cells were originally immortalized with an adenovirus
construct, bypassing normal regulators of the cell
cycle.
3.2. Generation of an HEK293 cell line expressing
tetracycline-inhibitable hPAX2a
We used the tetracycline-regulated expression sys-
w xtem of Gossens and Bujard 14 to establish an
HEK293 cell line expressing human PAX2a in the
absence of antibiotic. This system allows one to
regulate the level of hPAX2a expression by varying
the amount of tetracycline in the medium. The system
consists of two plasmids: p15-3rtTA constitutive
expression of a tRepressorrtTA fusion protein is
.driven by the cytomegalovirus promoter ; and p10-3
which carries a minimal CMV promoter and bacte-
.rial tetracycline operon sequences . The human
PAX2a cDNA was cloned into the multicloning site
of the p10-3 plasmid.
HEK293 cells were first co-transfected with p15-
3rtTA and SVNeo plasmids; thirty neomycin-re-
sistant colonies were selected and screened for opti-
mal tTA activity. In transient transfection assays with
a test reporter plasmid p10-3bGal, clonea3 exhibited
fully repressable bGal activity and was chosen for
second round of transfection with p10-3rhPAX2 and
pCMVrHygro. Eighteen hygromycin-resistant
colonies were selected and screened for tetracycline-
repressable hPAX2a expression by Western immuno-
 .blotting. A s seen in Fig. 1 A , clone
HEKrtTArhPAX2a a3-3 expresses hPAX2a pro-
tein, but in the presence of increasing concentrations
of tetracycline, hPAX2a expression is fully repressed.
Northern blots of HEKrtTArPAX2a a3–3 cell total
RNA probed with the hPAX2a cDNA showed the
 .same correlation data not shown . When cells are
transferred to medium without tetracycline, the cells
rapidly re-express hPAX2a protein within 3–6 h Fig.
 ..1 B .
Table 1
Markers 293 cells Condensed mesenchyme ‘‘S-shaped’’ body Proximal tubules Distal tubules Ref.
w xWT1 q q q y y 26
w xPAX2 q q q y y 10
w xWnt4 q q q y y 27
w xCytokeratin q y q q q 28
w xPAX8 y y q q y 21
w xAlkaline Phosphatase y y y q y 25
w xSLC3A1 y y y q y 22
w xPKD1 y y y q q 29
w xV2R y y y y q 30
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 .Fig. 1. A Western analysis of the PAX2 protein expression in
tetracycline-regulatable 293 tTArhPAX2 a3-3 cell line. Total
protein was extracted from cells grown in 0 mgrml;
0.0001 mgrml; 0.001 mgrml; 0.01 mgrml; 0.1 mgrml and
1mgrml of tetracycline for three days. Each lane contains 20 mg
of total protein. Arrow points to the PAX2 43–45 kDa protein.
 .B Western analysis of the PAX2 protein expression in 293
tTArhPAX2 a3–3 cell line after tetracycline removal. 293 cells
were grown in 1mgrml of the tetracycline-containing media for
three days. Tetracycline was removed from the media and cells
were collected for Western analysis at various times thereafter.
Each lane contains 20 mg of total protein. Arrow points to the
appearance of PAX2 protein expression in cells grown in tetra-
cycline-free media.
PAX2 is normally expressed as two alternatively
spliced isoforms, PAX2a and PAX2b, which differ
only in the presence of a 23 amino acid sequence
 . w xoutside the critical paired domain 10 . To ascertain
whether effects of hPAX2a were isoform-specific, we
also examined the phenotype of HEK293 cells stably
transfected with expression vectors encoding the two
 .murine isoforms mPAX2a and mPAX2b . In the
experiments below, all effects of hPAX2a expression
on HEKrtTArPAX2a a3–3 cell phenotype were
reproduced in cells stably overexpressing either
mPAX2a or mPAX2b. For simplicity, the results
below focus on data with hPAX2a in the tetra-
cycline-regulatable system.
3.3. Effect of PAX2 on HEK293 cell proliferation
To determine whether the rate of HEK293 cell
proliferation is influenced by PAX2 expression,
HEKrtTArhPAX2a a3–3 cells were plated at low
density, grown for 1–5 days in various concentra-
tions of tetracycline, trypsinized and counted. Neither
 .cell number Fig. 2 nor the rate of thymidine incor-
 .poration data not shown was affected by the level
of hPAXa protein expression. Similarly, cell number
and thymidine incorporation were equivalent in
HEK293 cells overexpressing mPAX2a, mPAX2b and
 .in controls data not shown .
3.4. Effect of PAX2 on expression of cytoskeletal
molecules
During the transition from undifferentiated mes-
enchyme to polarized epithelium, vimentin expres-
w xsion falls off before cytokeratins are induced 28,31 .
To determine whether PAX2 might be involved in
regulating these cytoskeletal changes, we assessed
steady state levels of vimentin and cytokeratin-18
transcripts by Northern analysis of total RNA from
HEKrtTArhPAX2a a3-3 in the presence or absence
of tetracycline. As seen in Fig. 3, the level of vi-
mentin mRNA is inversely proportional to the level
of hPAX2a protein. When assessed by densitometry
and normalized for GAPDH mRNA, maximal vi-
mentin expression was only 8% of control at high
Fig. 2. Effect of PAX2 protein expression on cell proliferation.
293 tTArhPAX2 a3-3 cells were plated 100000 per dish in
either tetracycline-free media, 0.005mgrml or 1mgrml of tetra-
cycline to allow high level, low level or no PAX2 expression,
.respectively . Cells were collected at 1–5 days and counted in a
hemocytometer. Each time point was done in duplicate. Each
experiment was repeated three times. No significant differences
in cell number were detected by ANOVA over the 5 days.
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Fig. 3. Northern Analysis: Effect of PAX2 on human vimentin
mRNA expression. Upper panel: In two separate experiments,
293 tTArhPAX2 cells were grown in the presence of 1mgrml
 . no PAX2 expression ; 0.005mgrml low level of PAX2 expres-
.  .sion or no tetracycline high level of PAX2 expression contain-
ing media and harvested at ;90% confluency. 20 mg of total
RNA were loaded into each lane: HFK human fetal kidney total
. RNA ; 293 293rneo cells grown in the same tetracycline-free
.media ; tTArhPAX2 samples as indicated. The blot was probed
with human vimentin cDNA and then reprobed with human
GAPDH to control for mRNA loading. Bottom panel: Densito-
metric analysis of human vimentin mRNA expression standard-
ized for GAPDH. Vimentin was significantly P - 0.021,
.ANOVA; P -0.05 Student-Newman-Keuls inhibited in dose-
dependent fashion by PAX2.
levels of hPAX2a expression P-0.021 ANOVA;
.P-0.05 Student-Newman-Keul . In contrast to vi-
mentin, cytokeratin-18 expression was unchanged by
 .hPAX2a Fig. 4 . The same selective suppression of
vimentin was seen in cells stably transfected with
 .either mPAX2a or mPAX2b data not shown .
3.5. Effect of PAX2 on transcription factors
In aggregating blastemal cells and the early
‘‘comma’’ and ‘‘S-shaped’’ body stages of nephron
formation, PAX2 and WT1 genes are co-expressed
w x9,11 . To investigate a potential link between the two
transcription factors, WT1 mRNA was assessed by
Northern analysis in HEKrtTArhPAX2a a3–3 cells
in the presence or absence of tetracycline. As seen in
Fig. 5, the level of endogenous WT1 mRNA rises as
PAX2 expression is increased 2-fold in the absence
Fig. 4. Northern Analysis: Effect of PAX2 on cytokeratin expres-
sion. Upper panel: In two separate experiments, 293 tTArhPAX2
cells were grown in media containing 1 and 0.005mgrml or no
tetracycline corresponding to no PAX2, low level of PAX2 or
high level of PAX2 protein, respectively. At ;90% confluency,
cells were harvested and total RNA was extracted. Each lane
contains 20 mg of total RNA: HFK human fetal kidney total
.  .RNA ; 293 293rneo cells grown in tetracycline-free media ;
tTArhPAX2 samples as indicated. The blot was probed with
human cytokeratin 18 cDNA and then reprobed with human
GAPDH as a loading control. Bottom panel: Densitometric analy-
sis of human cytokeratin mRNA expression standardized for
GAPDH. No significant effect of PAX2 on cytokeratin P )0.39,
.ANOVA was detected.
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Fig. 5. Northern Analysis: Effect of PAX2 on WT1 expression.
Upper panel: In two separate experiments, 293 tTArhPAX2 cells
were grown in media containing 1 and 0.005mgrml or no
tetracycline-containing media. 20 mg of total RNA was loaded
 . into each lane: HFK human fetal kidney total RNA ; 293 total
.RNA isolated from 293, neo cells ; tTArhPAX2 samples as
indicated. The blot was probed with human WT1 cDNA and then
reprobed with human GAPDH to control for loading. Bottom
panel: Densitometric analysis of WT1 mRNA expression stan-
dardized for GAPDH. WT1 mRNA was stimulated 2-fold P -
.0.033, ANOVA; P -0.05 Student-Newman-Keuls by PAX2.
of tetracycline; P-0.033 ANOVA; P-0.05 Stu-
.dent-Newman-Keuls .
3.6. Effect of PAX2 on cell adhesion molecules
Following induction, blastemal cells aggregate and
then proliferate along spatial planes defining the
tubular wall. Adjacent cells form specialized intercel-
lular junctions characteristic of epithelia specialized
for vectorial transport. In the transfilter model of
kidney development, Ekblom has shown that follow-
ing induction by spinal cord, metanephric cells begin
w xto express E-cadherin 32 .
Because levels of E-cadherin mRNA are relatively
low in segments of the fetal kidney tubule derived
from blastema, we used semi-quantitative RT-PCR to
assess changes in E-cadherin expression associated
with PAX2. Total RNA from HEKrtTArhPAX2a
a3-3 cells grown in the presence or absence of
tetracycline was reverse-transcribed with dT-oligo
primer, and E-cadherin cDNA was then amplified in
duplicate with specific primers at low cycle number
 .within the linear PCR range and quantified by
densitometry of Southern blots. The same reverse
transcriptase products were similarly assessed for
b-actin expression, and the E-Cadrb-actin ratio was
measured in three separate experiments. As seen in
Fig. 6, a 7-fold increase in endogenous E-cadherin
mRNA was associated with increasing hPAX2a ex-
 .pression P-0.01 Student t-test . We used the same
method to assess E-cadherin expression in mPAX2b
transfectants. Again, 5–10-fold stimulation of E-
cadherin mRNA was associated with PAX2 expres-
 .sion data not shown .
Fig. 6. Effect of PAX2 protein on E-cadherin mRNA expression.
In three separate experiments, 293 tTArhPAX2 cells were grown
in medium containing tetracycline at 1mgrml no PAX2 expres-
.  .sion, control or no tetracycline high PAX2 . Total RNA was
prepared from all cell samples and RT-PCR reactions were
carried out as described in Section 2. Southern blots of PCR
products for E-cadherin or b-actin were probed with human
E-cadherin and b-actin cDNAs, respectively. Films were ana-
lyzed densitometrically. Mean E-cadherin and b-actin signals and
mean E-cadherinrb-actin ratios are depicted for the high-tetra-
cycline or no-tetracycline conditions. E-cadherin expression was
 .significantly P -0.01, Student t-test stimulated 7-fold by
PAX2.
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4. Discussion
At the tips of each branch of the in-growing
ureteric bud, clusters of blastemal cells are induced to
aggregate and express a restricted set of new tran-
 .scription factors including PAX2 which are thought
to activate the developmental cascade. Little is known
about the initial effects of these transcription factors,
but as a member of the ‘‘paired-box’’ homeodomain
family, PAX2 is expected to act as a transcriptional
regulator of other genes and is essential for normal
w xnephrogenesis in rodents and humans 33 . In order to
identify effects of PAX2 that might be of relevance
to the early stages of nephrogenesis, we selected the
HEK293 human fetal kidney cell line for in vitro
studies. We found that these cells express markers
 .WT1, WNT4, cytokeratin of condensing mes-
enchyme and ‘‘S-shaped’’ body stage but not of
differentiated proximal or distal nephron segments
and low levels of PAX2 mRNA but no detectable
peptide. Taken together these features suggest that
HEK293 cells are a lineage derived from the induced
blastema and are suitable for eliciting PAX2 effects
relevant to the early stage of nephrogenesis.
4.1. PAX2 and proliferation of fetal kidney cells
One feature of PAX2-expressing cells in fetal kid-
ney is that they are highly proliferative. Intense stain-
 .ing for proliferating cell nuclear antigen PCNA is
seen in the induced blastemal and in early stages of
nephron formation, the ‘‘comma’’ and ‘‘S-shaped’’
w xbodies 34 . When stably transfected into NIH3T3
cells and rat 208 cells, PAX2 and other members of
w xthe PAX family are tumorigenic 35 . Cell prolifera-
tion was not directly assessed, but transfection with
several PAX cDNAs promoted colony growth in soft
agar and solid tumor formation when injected into
w xnude mice 35 . Gnarra has shown that renal carci-
 .noma cells RCC express high levels of PAX2 pro-
tein and that when RCC cells are exposed to anti-
sense PAX2 oligonucleotides in vitro, the cells are
w xgrowth inhibited 36 . Furthermore, PAX2, PAX5
and PAX8 were found to suppress transcription of
p53, a critical regulator of the cell cycle in rodent
w xfibroblasts 37 . In our experiments, however,
HEK293 cells expressing PAX2 exhibited no change
in basal proliferative rate. Conceivably, PAX2 might
influence proliferation of fetal kidney cells in vivo by
enhancing responsiveness to local growth factors not
present in cultured HEK293 cells. However, it is
more likely that the direct effects of PAX2 on
HEK293 cell proliferation are masked by cell cycle
effects of the adenovirus reagent initially employed
to immortalize this particular cell line.
4.2. PAX2 and regulation of WT1
Because PAX2 and WT1 are co-expressed in the
induced blastema and both transcription factors are
expressed at high levels in Wilms’ tumors, it has
been postulated that PAX2 might normally partici-
pate in the transcriptional activation of WT1 expres-
sion. We found that the endogenous level of WT1
mRNA was moderately elevated by PAX2. Similarly,
w xin HEK293 cells, both Dehbi et al. 38 and Mc-
w xConnell et al. 39 have reported stimulation of WT1
promoter activity when co-transfected with PAX2.
Both authors reported even greater stimulation 8–
.35-fold in non-renal cell lines and Dehbi noted
marked stimulation of endogenous WT1 mRNA in
w xthe K562 keratinocyte line 38 . Taken together, these
observations suggest that PAX2 might enhance WT1
expression in developing kidney. However, the situa-
tion in vivo appears to be complex. PAX2 mRNA is
clearly present in cells of the branching ureteric bud
w xwhich lack WT1 expression 9,10 . Conversely, PAX2
is absent in podocytes of the fetal glomerulus where
w xWT1 expression is highest 40 . Thus, while PAX2
may influence WT1 transcription in some settings,
possibly in condensing mesenchyme, alternative tis-
sue-specific regulators of WT1 are likely to dominate
at other sites.
4.3. PAX2 and the mesenchyme to epithelium transi-
tion
Following contact with the ureteric bud,
metanephric mesenchymal cells undergo a radical
phenotypic transformation to form the polarized ep-
w xithelium lining an ‘‘S-shaped’’ vesicle 32 . These
changes have been examined using the transfilter
model of renal development in which induction of
undifferentiated mesenchyme is initiated by co-cul-
( )E. Torban, P.R. GoodyerrBiochimica et Biophysica Acta 1401 1998 53–62 61
w xture with explants of fetal spinal cord 31 . In the
uninduced mesenchyme, N-CAM is the only identifi-
w xable cell attachment molecule 41 ; N-CAM is gradu-
ally replaced by E-cadherin as the ‘‘S-shaped’’ body
w xforms 32,41 . In this study, we found that expression
of PAX2 in HEK293 cells was associated with a
7-fold increase in steady state E-cadherin mRNA.
This is consistent with the observation that PAX2 is
expressed in condensing mesenchyme and the ‘‘S-
shaped’’ body just as E-cadherin expression begins.
Conversion of mesenchyme to polarized epithe-
lium also involves alteration of the cytoskeleton.
Cultured human mesothelial cells proliferating in un-
supplemented medium have a spindle-shaped mor-
phology and express high levels of vimentin, but
w xminimal cytokeratins 17 ; in response to retinoic
acid, the cells take on an epithelial appearance, sup-
press vimentin and express high levels of cytoker-
w xatins 17 . Lehtonen has examined the rearrangement
of intermediate filaments in the transfilter model of
w xnephron induction 28 . In the uninduced mes-
enchyme he noted strong immunoreactivity for vi-
mentin. After two days, he was able to detect cellular
aggregates corresponding to mesenchymal conden-
w xsates associated with PAX2 expression in vivo 28 .
By the 3rd day, early tubular structures were identifi-
able in which vimentin was completely absent. By
the 4th day, cytokeratin was evident in the tubular
structures. Similarly, in human fetal kidney, Matsell
has shown that vimentin immunoreactivity is intense
in uninduced blastema, barely detectable in the ‘‘S-
shaped’’ stage and absent in maturing proximal tubule
w x42 . In our study, we have shown that PAX2 dramat-
ically suppresses vimentin mRNA to 8% of controls,
while cytokeratin-18 was unchanged or modestly in-
creased. We speculate that, in condensing mes-
enchyme and the early ‘‘S-shaped’’ stage of nephro-
genesis, intense PAX2 expression may serve to sup-
press the mesenchymal intermediate filament, vi-
mentin, in anticipation of a switch to epithelial cytok-
eratins.
Our experiments do not determine whether PAX2
acts directly or indirectly, but its effects on expres-
sion of WT1, E-cadherin and vimentin in HEK293
cells mimick the changes which normally occur in
PAX2-positive mesenchymal condensates and ‘‘S-
shaped’’ bodies during the early stages of nephrogen-
esis.
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